The 2022 KDIGO guidelines for diabetes management in CKD recommend the use of metformin and SGLT2 inhibitors for all patients with T2DM, CKD, and an GFR > 30 mL/min/1.73 m2 [63]. This evidence concerns the gene SLC5A2 and diabetes mellitus.